*Disseminated on behalf of Medicus Pharma Ltd.
Market Crux Announces Coverage Announces Coverage On (MDCX) Starting
This Morning—Tuesday, July 8, 2025.
And Here's Why…
Analyst Targets From D Boral Capital And Maxim Group On (MDCX) Suggest Potential Upside Ranges Of Around 560% To 800%.
Ultra Low Float: With Less Than 2.5 Mln Shares Listed As Available For The Public, (MDCX) Could Witness Significant Swing Potential If Demand Begins To Shift.
Key Technical Levels Are Being Watched As (MDCX) Hovers Near Thresholds Often Tracked For Momentum.
Phase 2 Clinical Progress Continues For (MDCX) With SkinJect Showing Encouraging Response Rates.
Antev Acquisition Announced By (MDCX) In June Expands Its Pipeline Into Advanced Prostate Care And Urinary Retention Markets Estimated Over $6B Annually.
FDA Submission By (MDCX) Advances Its Microneedle Patch Into Veterinary Oncology Targeting Equine Care.
Focus On Non Invasive Care For Basal Cell Carcinoma Aligns (MDCX) With A Projected $15B Market In North America By 2030.
Take A Look (MDCX) While It's Still Early…
July 8, 2025 Here It Is: (MDCX) is Lighting Up Our Early Radar—Take a Quick Look
Dear Reader, Here it is—the bell just rang and (MDCX) is lighting up our early radar. Few sectors move faster than biotech and pharma, where a single advancement can launch a little-known company directly into the spotlight. This is especially true when the focus is on conditions that touch so many lives, with methods that could change how care looks and feels for patients. When early results begin to align with what many have hoped was possible, attention starts to follow. That's where Medicus Pharma Ltd. (NASDAQ: MDCX) stands right now. But keep in mind, (MDCX) has a very limited float, with fewer than 2.5 Mln shares listed as available to the public according to FinViz. Insider ownership is also reported at over 80%, a level that could reflect a management team's confidence in the company's direction. Analyst's $27 Target Suggests Over 800% Upside Potential
Multiple news sites and market portals, including Benzinga, GuruFocus, MarketWatch, and TipRanks, have reported that D. Boral Capital analyst Jason Kolbert recently set a $27 target on (MDCX), which suggests over 800% potential upside from its recent $3 range. That's not the only target we're tracking. In a recently published report, Maxim Group's Jason McCarthy set a $20 target on (MDCX), indicating over 560% potential from current levels. On the technical side, (MDCX) has been hovering around several key levels, a pattern that merits close attention as its broader story continues to take shape. Not Your Typical Pharma Story At its core, (MDCX) is not just another player in the life sciences space—it is positioning itself at the forefront of non-invasive, patient-friendly care across multiple continents. See the company's corporate presentation here. Using a patented microneedle patch technology, (MDCX)'s SkinJect subsidiary targets basal cell carcinoma (BCC), aiming to replace invasive, often painful surgical procedures with an alternative that could reshape patient care. 
BCC is the most common form of cancer globally, impacting over 5 Mln individuals annually in the United States alone, with rates expected to rise as populations age and sun exposure accumulates. Traditional solutions like Mohs surgery remain effective but can be costly, painful, and leave patients with scarring and extended recovery times. The SkinJect microneedle patch seeks to address these challenges by providing a simple, painless, office-based treatment using a dissolvable patch to deliver doxorubicin directly to the tumor site. (MDCX) recently announced it has entered into a definitive agreement to acquire Antev Ltd., a clinical-stage biotech company developing Teverelix—a next-generation GnRH antagonist targeting advanced prostate care and acute urinary retention in high-need patient groups. 
Antev's programs include FDA-cleared Phase 2b studies in both indications, aiming to address significant markets in the U.S. for advanced prostate cancer and recurrent urinary retention, with potential annual addressable market potential exceeding $6B combined. Through this acquisition, (MDCX) is broadening its pipeline while maintaining its focus on advancing patient-friendly treatments in areas of clear medical need, reinforcing its commitment to delivering practical innovations in both oncology and men's health. Backed by Exclusive IP and a Clear Market Need
Medicus, through SkinJect, holds exclusive worldwide development and commercialization rights from Carnegie Mellon University and the University of Pittsburgh, with issued U.S. patents extending through 2035. This intellectual property underpins Medicus' potential to carve out a distinct place in a projected $15B North American market for skin cancer treatments by 2030. SkinJect's targeted approach aligns with a clear medical need for effective, non-surgical options, especially among elderly and inoperable patients where surgery may not be feasible. The patch is designed to offer efficacy comparable to Mohs surgery while significantly reducing patient discomfort and downtime. Bridging a Critical Gap in Cancer Care
What makes Medicus truly unique is its ability to bridge the gap between the effectiveness of surgery and the convenience of topical treatments. Many topical therapies fall short of delivering meaningful outcomes, while surgery, although effective, demands significant resources and healing time. SkinJect's microneedle technology offers a middle ground, aligning with the healthcare industry's shift toward minimally invasive, patient-centric treatment models that reduce system strain while maintaining quality outcomes. Why This Matters Now
SkinJect's approach is part of a larger healthcare shift toward effective, minimally invasive, and accessible treatments, addressing the demand for therapies that improve outcomes while reducing the burden on patients and the system. With its innovative technology, strong intellectual property portfolio, and promising early data, (MDCX) is aiming to redefine how a widespread and growing condition like basal cell carcinoma is managed. Recent Developments
June 30, 2025
Medicus Pharma Announces Acquisition Agreement with Antev Ltd. (UK)
(MDCX) announced it has signed a definitive agreement to acquire Antev Ltd., a UK-based clinical-stage biotech company. Under the agreement, Antev shareholders will receive approximately 17% equity in Medicus along with up to $65M in contingent milestone payments tied to potential FDA Phase 2 and New Drug Application approvals. Antev is developing Teverelix, a next-generation therapy candidate for advanced prostate conditions and acute urinary retention, with FDA-approved Phase 2b studies planned across the U.S. and Europe. This acquisition, expected to close by the end of August 2025, positions Medicus to expand its clinical pipeline while maintaining its focus on targeted, patient-centered treatment solutions. 
June 5, 2025
Medicus Pharma Advances Veterinary Oncology Program with FDA Submission
Earlier in June, (MDCX) submitted a comprehensive product development plan to the FDA to advance its doxorubicin-containing microneedle patch for veterinary oncology, targeting external squamous cell carcinoma (SCC) in horses. Following its Minor Use in Major Species (MUMS) designation, which offers benefits similar to orphan drug status in human medicine, Medicus' submission could provide seven years of market exclusivity upon approval. The company estimates a potential market of $250M in this under-addressed segment of veterinary care, aligning with its mission to expand the reach of its patented microneedle platform into areas of high need. These recent moves underscore how (MDCX) is actively expanding its reach while staying focused on patient-friendly treatment strategies. As the company executes on its plans across human and veterinary care, momentum is starting to build around its broader story. Here's a closer look at why (MDCX) has moved to the top of our radar right now: 7 Reasons Why (MDCX) is Topping Our Watchlist Right Now
1. Recent Analyst Coverage: Multiple market portals have noted that D. Boral Capital and Maxim Group have both issued notable targets on (MDCX)—reflecting potential upside in the range of approximately 560% to 800%.
2. Ultra Low Float: With fewer than 2.5 Mln shares listed as available to the public, (MDCX) sits in a rare category where any shift in demand could lead to the potential for significant swings. 3. Technical Levels Eyed: We're keeping a close eye on (MDCX) as it trends near key thresholds that are often monitored for potential momentum. 4. Phase 2 Advancement: Clinical progress is underway for (MDCX) as it pushes its SkinJect platform through Phase 2 trials with interim data showing encouraging complete response rates. 5. Pipeline Expansion Moves: In June, (MDCX) announced an agreement to acquire Antev Ltd., aiming to strengthen its pipeline with programs in advanced prostate care and acute urinary retention—areas with an estimated combined market potential exceeding $6B annually. 6. Large Market Focus: By focusing on non-invasive care for basal cell carcinoma, (MDCX) is aligning with a clear medical need in a projected $15B North American market by 2030. 7. FDA Submission: A submission to the FDA was recently made by (MDCX) to advance its microneedle patch into veterinary oncology, expanding its reach into equine care. All of this points to (MDCX) moving with intention while aligning its efforts with high-need markets. It's the kind of situation that doesn't come across the screen every day. If you haven't looked at (MDCX) yet, now may be the time to get it on your radar while it's still early. Get (MDCX) On Your Screen While It's Still Quiet…
(MDCX) has positioned itself as a company actively advancing patient-centered care while drawing notable analyst attention. D. Boral Capital recently set a $27 target on (MDCX), suggesting approximately 800% upside potential from recent levels, while Maxim Group issued a $20 target which suggests around 560% upside potential. Alongside these signals, (MDCX) announced plans in June to acquire Antev Ltd., a clinical-stage biotech developing treatments for advanced prostate care and acute urinary retention, expanding its pipeline into markets estimated to exceed $6B annually in combined addressable demand. Combined with its ongoing SkinJect Phase 2 advancement and its move into veterinary oncology, (MDCX) is aligning its efforts with areas where better solutions are needed. With a clear focus on non-invasive care for basal cell carcinoma, (MDCX) is aligning itself with a projected $15B North American market by 2030. (MDCX) is at the top of our screen this morning. (Tuesday—July 8, 2025)
Get (MDCX) on your radar while it's still early.. My next update could be out at any moment—please make sure you're keeping an eye out for it. Sincerely, Gary Silver
Managing Editor, Market Crux | 
No comments:
Post a Comment